Compare NDLS & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NDLS | PLRX |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.7M | 74.9M |
| IPO Year | 2013 | 2020 |
| Metric | NDLS | PLRX |
|---|---|---|
| Price | $12.33 | $1.19 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $2.67 |
| AVG Volume (30 Days) | 59.2K | ★ 479.9K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $495,089,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.37 | N/A |
| 52 Week Low | $0.47 | $1.09 |
| 52 Week High | $13.95 | $1.95 |
| Indicator | NDLS | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 62.93 | 41.56 |
| Support Level | $0.60 | $1.16 |
| Resistance Level | $13.95 | $1.37 |
| Average True Range (ATR) | 1.08 | 0.04 |
| MACD | -0.12 | -0.00 |
| Stochastic Oscillator | 53.77 | 35.71 |
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services. It is focused on offering customers flavorful, cooked-to-order dishes in a warm and welcoming environment at an attractive value. It has approximately 340 company-owned restaurants and 83 franchise restaurants in 31 states.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.